Godbout Sean 4
4 · BIOGEN INC. · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Biogen (BIIB) Chief Accounting Officer Sean Godbout Receives Award
What Happened Sean Godbout, Chief Accounting Officer of Biogen (BIIB), was granted 1,800 restricted stock units (RSUs) on February 13, 2026. The grant shows an acquisition price of $0.00 (standard for RSU awards); there was no cash paid. This is an equity award (not an open‑market purchase or sale) and reflects compensation rather than an immediate market bet.
Key Details
- Transaction date: 2026-02-13; reported on Form 4 filed 2026-02-17 (timely filing).
- Security and amount: 1,800 restricted stock units (derivative award) at $0.00 acquisition price.
- Vesting: RSUs vest in three equal yearly installments beginning on the first anniversary of the grant (i.e., likely 600 RSUs vest annually starting Feb 13, 2027). (Footnote F1)
- Shares owned after transaction: Not specified in this filing.
- Transaction code: A = Award/Grant. No 10b5-1 plan, tax‑withholding, or late‑filing flags noted.
Context RSUs are a form of compensation that convert into common shares as they vest; they do not represent an immediate cash purchase or sale. Such grants are common for executives and do not by themselves signal a buy/sell opinion on the stock. This filing simply documents the grant and its vesting schedule.
Insider Transaction Report
- Award
Restricted Stock Unit
[F1]2026-02-13+1,800→ 1,800 totalExercise: $0.00Exp: 2029-02-13→ Common Stock (1,800 underlying)
Footnotes (1)
- [F1]The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.